Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 2018 Dec 21;63(1):e01396-18. doi: 10.1128/AAC.01396-18

OXA-48-Like-Producing Klebsiella pneumoniae in Southern Spain in 2014–2015

Jesús Machuca a,b,c, Lorena López-Cerero a,b,c,d,, Felipe Fernández-Cuenca a,b,c, Laura Mora-Navas e, Concepción Mediavilla-Gradolph f, Inmaculada López-Rodríguez g, Álvaro Pascual a,b,c,d
PMCID: PMC6325174  PMID: 30323046

The aim of this study was to characterize the population structure of 56 OXA-48-like-producing Klebsiella pneumoniae isolates, as well as extended-spectrum β-lactamase (ESBL) and carbapenemase genes, recovered in 2014 and 2015 from 16 hospitals in southern Spain. XbaI pulsed-field gel electrophoresis and multilocus sequence typing were performed to assess clonal relatedness.

KEYWORDS: Klebsiella pneumoniae, OXA-48, southern Spain

ABSTRACT

The aim of this study was to characterize the population structure of 56 OXA-48-like-producing Klebsiella pneumoniae isolates, as well as extended-spectrum β-lactamase (ESBL) and carbapenemase genes, recovered in 2014 and 2015 from 16 hospitals in southern Spain. XbaI pulsed-field gel electrophoresis and multilocus sequence typing were performed to assess clonal relatedness. Representative isolates belonging to OXA-48-like-producing and CTX-M-15-coproducing pulsotypes were selected for characterization of blaOXA-48-like- and blaCTX-M-15-carrying plasmids by PCR-based replicon typing, IncF subtyping, whole-genome sequencing analysis, and typing of Tn1999 structures. Forty-three OXA-48-producing isolates (77%) were recovered from clinical samples and 13 from rectal swabs. All isolates showed ertapenem MIC values of ≥1 mg/liter, although 70% remained susceptible to imipenem and meropenem. Forty-nine isolates (88%) produced OXA-48, 5 produced OXA-245, and 2 produced OXA-181. Twenty-eight different pulsotypes (5 detected in more than 1 hospital) and 16 sequence types (STs) were found. The most prevalent clones were ST15 (29 isolates [52%]) and ST11 (7 isolates [13%]). Forty-five (80%) isolates were also blaCTX-M-15 carriers. The blaCTX-M-15 gene was mostly (82%) located on IncR plasmids, although ST15 and ST11 isolates also carried this gene on IncF plasmids. The composite transposon variant Tn1999.2-like was the most frequent. Among ST15 and ST11 isolates, different transposon variants were observed. The blaOXA-48 gene was mainly located on IncL plasmids, although IncM plasmids were also observed. The spread of OXA-48-like-producing K. pneumoniae in southern Spain is mainly due to ST15 and ST11 clones. Variation within clonal lineages could indicate different acquisition events for both ESBL and carbapenemase traits.

INTRODUCTION

The most important carbapenemases in Enterobacteriaceae are the KPC (class A), NDM, IMP, VIM (class B), and OXA-48 (class D) types (1). Among carbapenemase-producing microorganisms, the increasing number of OXA-48-producing Enterobacteriaceae, mainly Klebsiella pneumoniae, is becoming a serious threat, particularly in Europe (2). OXA-48 was first observed in a clinical isolate of K. pneumoniae in Turkey in 2001 (3). Since that time, it has spread across North Africa and Europe (1). OXA-48-type carbapenemases hydrolyze penicillins and carbapenems but show weak activity against extended-spectrum cephalosporins (3). Isolates harboring blaOXA-48 also carry other β-lactamase genes, such as blaCTX-M-15 and blaOXA-1, resulting in resistance to cephalosporins and amoxicillin/clavulanate (4). In Spain, increasing numbers of cases of carbapenemase-producing Enterobacteriaceae (CPE) have been reported in recent years. In a Spanish multicenter study performed in 2012, the most common CPE type detected as a cause of nosocomial outbreaks and individual infections was OXA-48-producing K. pneumoniae (5).

Dissemination of OXA-48 is principally related to the spread of a highly transferable IncL/M plasmid carrying only blaOXA-48-like genes as resistance determinants (6). The blaOXA-48 gene is carried by the Tn1999.1 transposon or its variants Tn1999.2 and Tn1999.3 (with 1 or 2 copies, respectively, of IS1R inserted into IS1999) (7). Two new variants of Tn1999.2 have recently been reported, namely, Tn1999.4 and Tn1999.5, in which the lysR gene is truncated by Tn2015 and ISKpn19, respectively (8, 9). Despite the growing prevalence of OXA-48 producers, little is known regarding the prevalence or genetic environment of blaOXA-48 and its accompanying resistance determinants in Spain.

In 2014 and 2015, 16 hospital laboratories in Andalusia (southern Spain) submitted 276 K. pneumoniae isolates of non-wild-type carbapenem susceptibility (10), both single and clustered in time, to the reference laboratory of the PIRASOA program (Hospital Universitario Virgen Macarena, Seville, Spain). A total of 177 isolates (64%) were confirmed to be carbapenemase producers; 56 isolates (32%) were OXA-48-like producers and the remainder were KPC-3 producers. The resistance determinants (blaOXA-48-like and blaCTX-M-15 genes), plasmids, Tn1999-type composite transposons, and population structure of OXA-48-like-producing K. pneumoniae isolates were characterized.

RESULTS AND DISCUSSION

Patients and isolates.

Forty-three OXA-48-like-producing K. pneumoniae isolates (77%) came from clinical samples, distributed as follows: urine, 23 isolates (41%); blood, 8 isolates (14%); wounds, 6 isolates (11%); sputum, 2 isolates (4%); bile, 2 isolates (4%); catheter tip, 1 isolate (2%); ascitic fluid, 1 isolate (2%). Thirteen isolates (23%) came from rectal swabs (see Table S2 in the supplemental material). Two groups of isolates were recovered from outbreak investigations in hospitals (9 and 5 isolates from hospital H8), and the remainder were sporadic isolates.

Antibiotic susceptibility and antibiotic resistance genes.

All isolates were nonsusceptible to amoxicillin-clavulanic acid, piperacillin-tazobactam, temocillin, and ertapenem. Thirty-nine isolates (70%) remained susceptible to both imipenem and meropenem. Susceptibility to other antibiotics was as follows: ceftazidime and aztreonam, 18%; cefotaxime and cefepime, 11%; ciprofloxacin, 12%; gentamicin, 73%; tobramycin, 23%; amikacin, 77%; fosfomycin, 54%; trimethoprim-sulfamethoxazole, 29% (Table S2). All isolates showed positive results for imipenem hydrolysis using the β-Carba assay.

Three OXA-48 variants were identified; blaOXA-48 was identified in 49 (87.5%) of 56 isolates, blaOXA-245 in 5 isolates (8.9%), and blaOXA-181 in 2 isolates (3.6%) (Table 1; also see Table S2). OXA-48 predominated over other variants, which coincides with the results of other surveys in which OXA-48 was the most widespread (11, 12). OXA-181 was first identified in India and has been reported in many different countries (United Kingdom, Canada, Australia, and Japan) (1). To our knowledge, this is the first report of the blaOXA-181 gene in Spain. The OXA-181-producing isolates came from Almeria and Cordoba. The blaOXA-245 gene was first detected in Spain in a hospital outbreak in Malaga (13), and 4 of 5 OXA-245-producing isolates came from hospitals in Malaga.

TABLE 1.

Molecular epidemiology and antibiotic resistance gene characterization for OXA-48-like-producing K. pneumoniae isolates

ST Pulsotype No. of
isolates
Geographical
areaa
Hospital blaOXA-48-like blaOXA-48-like
plasmid type
Tn1999
variantb
blaCTX-M-15 blaCTX-M-15
plasmid typec
pAmpC
(blaCMY-2)
ST15 P01 1 Seville H16 blaOXA-48 IncL 2, 4, or 5 Yes IncR No
P02 12 Malaga (n = 9),
Seville (n = 3)
H13 (n = 9),
H16 (n = 3)
blaOXA-48 IncL 2, 4, or 5 Yes (n = 9) IncR No
P03 7 Malaga (n = 4),
Seville (n = 2),
Granada (n = 1)
H5 (n = 1),
H8 (n = 2),
H13 (n = 2),
H14 (n = 1),
H16 (n = 1)
blaOXA-48 IncL 1 Yes (n = 6) IncR No
P04 1 Cordoba H6 blaOXA-48 IncL 2, 4, or 5 Yes IncR No
P05 5 Malaga H8 blaOXA-48 IncL 1 Yes IncR No
P06 1 Seville H16 blaOXA-48 IncL 2, 4, or 5 Yes FIIK7:A−:B− No
P07 2 Seville (n = 1),
Malaga (n = 1)
H11 (n = 1),
H13 (n = 1)
blaOXA-48 IncL 1 Yes IncR No
ST11 P08 2 Malaga H3 (n = 1),
H13 (n = 1)
blaOXA-48 IncL 2, 4, or 5 Yes IncR No
P09 1 Malaga H3 blaOXA-245 IncL 1 Yes IncR No
P10 2 Malaga H13 blaOXA-48 IncL 2, 4, or 5 Yes IncR No
P11 2 Jaen (n = 1),
Cadiz (n = 1)
H4 (n = 1),
H12 (n = 1)
blaOXA-48 No TF 2, 4, or 5 Yes FIIK1:A−:B− No
ST1 P12 1 Malaga H13 blaOXA-245 IncL 2, 4, or 5 Yes No TF Yes
P13 1 Malaga H13 blaOXA-48 IncL 2, 4, or 5 Yes IncR Yes
P14 1 Jaen H1 blaOXA-245 IncL 2, 4, or 5 Yes No TF No
ST147 P15 1 Cordoba H9 blaOXA-181 No TF ND Yes No TF No
ST392 P16 2 Seville H16 blaOXA-48 IncM 1 No No
P17 1 Seville H16 blaOXA-48 IncM 2, 4, or 5 No No
P18 2 Seville H15 blaOXA-48 No TF 1 Yes FIIK7:A−:B− No
ST17 P19 2 Seville H16 blaOXA-48 IncL 2, 4, or 5 Yes (n = 1) FIIK7:A−:B− No
ST225 P20 1 Jaen H4 blaOXA-48 IncL 2, 4, or 5 No No
ST251 P21 1 Malaga H3 blaOXA-245 IncL 1 No No
ST307 P22 1 Seville H10 blaOXA-48 IncL 2, 4, or 5 Yes FIIK7:A−:B− No
ST391 P23 1 Seville H16 blaOXA-48 IncL 2, 4, or 5 Yes IncR No
ST405 P24 1 Malaga H3 blaOXA-245 IncL 2, 4, or 5 Yes FIIK7:A−:B− No
ST431 P03 1 Malaga H3 blaOXA-48 IncL 2, 4, or 5 Yes No TF No
ST753 P25 1 Cadiz H2 blaOXA-48 IncL 2, 4, or 5 No No
ST836 P26 1 Almeria H7 blaOXA-181 No TF ND Yes No TF No
ST899 P27 1 Malaga H8 blaOXA-48 IncL 2, 4, or 5 No No
ST974 P28 1 Seville H5 blaOXA-48 IncL 2, 4, or 5 No No
a

Numbers of isolates are indicated for geographical areas, hospitals, and CTX-M-15 coproducers.

b

ND, not determined.

c

No TF, no transformants were obtained.

Forty-five isolates (80%) in this study also coharbored blaCTX-M-15 genes (Table 1), as in previous studies (4, 13). Only 2 isolates (4%) coproduced CMY-2, CTX-M-15, and OXA-48-like β-lactamases. Two OXA-48-producing isolates (4%) coproduced the extended-spectrum β-lactamase (ESBL) SHV-27. While there have been frequent reports worldwide of the coexistence of OXA-48-like and other class A and B carbapenemases in K. pneumoniae (1), none of our isolates coproduced other carbapenemases.

Molecular epidemiology.

Pulsed-field gel electrophoresis (PFGE) analysis of XbaI digests revealed 28 well-defined pulsotypes (1 to 12 isolates/pulsotype), and multilocus sequence typing (MLST) analysis found 16 sequence types (STs) (Table 1; also see Table S2 and Fig. S1). ST15 (29 isolates [51.8%]) and ST11 (7 isolates [12.5%]) accounted for more than one-half of the isolates. ST15 isolates were detected in 7 hospitals in different geographical areas. Among the ST15 isolates, 7 different pulsotypes (pulsotypes P01 to P07) were observed, 1 of which (pulsotype P03 [7 isolates]) was detected in 5 hospitals, i.e., 2 isolates each in 2 hospitals with high patient flows in the same province and 3 isolates in 3 hospitals, one each, with no epidemilogical link. Two pulsotypes were detected in 2 hospitals (pulsotype P02, 12 isolates; pulsotype P07, 2 isolates) in different geographical areas (Table 1). Pulsotype P07 clustered with the other ST15 pulsotypes with less than 60% similarity, and the other 6 pulsotypes shared more than 80% similarity. ST11 isolates were detected in 4 hospitals and showed 4 different pulsotypes (pulsotypes P08 to P11), 2 of which (pulsotype P08, 2 isolates; pulsotype P11, 2 isolates) were detected in different hospitals with no known epidemiological link. According to pulsotype, 3 ST15 pulsotypes (pulsotypes P02, P03, and P07) and 2 ST11 pulsotypes (pulsotypes P08 and P11) were detected in more than 1 hospital (26 isolates).

The ST15 clone carrying ESBLs and carbapenemases is distributed worldwide, notably in Europe (14). OXA-48-like-producing K. pneumoniae isolates belonging to ST15 were detected previously in Spain, France, Bulgaria, and other countries (1517), although this ST has frequently been associated with KPC- and VIM-producing K. pneumoniae isolates (1). In a previous multicenter survey of hospitals in all parts of Spain in 2012 and 2013, ST11 and ST405 were the most prevalent STs detected among OXA-48-producing K. pneumoniae isolates (16). In the present study in the south of Spain, in contrast, ST15 was more prevalent than ST11 and also was more widely distributed (7 hospitals versus 4 hospitals). The main immigrant population in the south of Spain comes from the Maghreb. OXA-48-producing K. pneumoniae isolates belonging to ST15 and ST11 were detected in a hematology unit in Tunisia (18), although the most important clones associated with the dissemination of OXA-48 in these countries are different (e.g., ST147, ST307, and ST395) (19, 20). It was thought that OXA-48 producers caused mainly sporadic cases, with less interhospital transmission than other carbapenemase producers, although several examples of the interhospital spread of blaOXA-48 were observed with ST395 and ST101 in Hungary (21, 22). Concurrent with transmission of ST15 and ST11 in our area, a single pulsotype was detected in 10 hospitals and more than 1 pulsotype was detected in 6 hospitals. The number of isolates belonging to the ST15 clone in our area decreased from 22 (69%) in 2014 to 7 (29%) in 2015.

Only 1 isolate belonging to ST405 was detected. This clone was previously responsible for a major nosocomial outbreak of OXA-48-producing K. pneumoniae in a hospital in Madrid (center of Spain), as well as in other regions in Spain (23). In Andalusia, the same clone was responsible for an outbreak due to CTX-M-15-producing K. pneumoniae lacking the blaOXA-48 gene (24).

Genetic context of OXA-48-like genes and characterization of OXA-48 and CTX-M-15 plasmids.

OXA-48-like enzymes are frequently carried on the epidemic IncL-type plasmid, which is responsible for the worldwide dissemination of blaOXA-48-like genes. The blaOXA-181 gene has been located on IncT and IncX3 plasmids (25). In order to gain some insight into the type of transmission of blaOXA-48 and blaCTX-M-15 genes, plasmids recovered from transformants were analyzed. Escherichia coli DH10B transformants producing OXA-48-like carbapenemases were obtained from 24 (79%) of 28 selected isolates, which were representative of the pulsotypes detected. No transformants were obtained from OXA-181 producers. Using the PCR-based replicon typing (PBRT) scheme, 22 pulsotypes (48 isolates) carrying blaOXA-48-like plasmids belonged to the IncL compatibility group (Table 1; also see Table S2), which is consistent with the recognized IncL plasmid pOXA-48, responsible for the international dissemination of OXA-48 (26). In 2 pulsotypes (pulsotypes P16 and P17), the blaOXA-48 gene was located on an IncM plasmid, a result that was confirmed by whole-genome sequencing (WGS), indicating a new incRNAI region with respect to M1 and M2, M3. To our knowledge, this is the first description of the blaOXA-48 gene located on a new IncM3 plasmid. These 2 pulsotypes belonged to ST392.

Twenty-six representative isolates of every pulsotype were selected for characterization of transposon Tn1999. OXA-181 producers were not included, because blaOXA-181 is generally located on Tn2013 (27). The composite transposon variant Tn1999.2 (with the left IS1999 truncated by IS1R) (28), or its variants Tn1999.4 and Tn1999.5, was detected in 19 pulsotypes (65.5%) (Table 1). Sixteen and 3 pulsotypes carried OXA-48 and OXA-245, respectively. The Tn1999.1 variant (with IS1999 intact and IS1R absent) (29) was less prevalent and was detected in 8 pulsotypes (27.5%). This isoform was found in 6 pulsotypes linked to OXA-48 and in 2 pulsotypes associated with OXA-245. Tn1999.3 (with both the upstream and downstream IS1999 truncated by IS1R) (7) was not found. Different isoforms of Tn1999 were detected in 3 clones, namely, ST15, ST11, and ST392. In the ST15 clone, Tn1999.2-like was found in 4 pulsotypes (15 isolates [52%]) and Tn1999.1 was found in 3 pulsotypes (14 isolates [48%]). In clone ST11, the Tn1999.1 variant was detected in only 1 pulsotype (1 isolate [14%]), while Tn1999.2 (or its variants) was detected in 3 pulsotypes (6 isolates [86%]). In clone ST392, Tn1999.1 was detected in 1 pulsotype and Tn1999.2-like was detected in the other pulsotype of this clone. These findings are consistent with different lineages of the same clone acquiring the blaOXA-48 gene on separate occasions and other plasmids spreading this determinant.

Among the 28 pulsotypes detected in our set of isolates, only 21 included CTX-M-15-producing isolates. CTX-M-15-producing E. coli DH10B transformants were obtained from 18 pulsotypes (with none obtained from pulsotypes P12, P14, and P15). Only 6 plasmids could be typed using the PBRT scheme (Table 1) (30, 31), and all were IncFII-type; 5 pulsotypes yielded the FIIK7:A−:B− formula (including pulsotype P06, an ST15 pulsotype), and 1 pulsotype yielded the FIIK1:A−:B− formula. Because the PBRT scheme targets only replicons of the major plasmid families in Enterobacteriaceae, WGS was used to characterize the CTX-M-15 plasmid of the other 12 pulsotypes. Those 12 pulsotypes carried the blaCTX-M-15 gene on IncR-type plasmids (Table 1), which is different from findings published previously in the literature, in which blaCTX-M-15 was located principally on IncF plasmids (32). The association between the blaCTX-M-15 gene and IncR plasmids was described previously for K. pneumoniae isolates belonging to successful clones (ST15, ST11, and ST147) in Europe (33, 34). In our study, most ST15 isolates coharboring blaCTX-M-15- and blaOXA-48 (25 isolates from 6 pulsotypes) carried the blaCTX-M-15 gene on an IncR plasmid; only the isolate with pulsotype P06 carried it on an IncFII-type plasmid. With respect to ST11 isolates, blaCTX-M-15 was located on IncR plasmids in 3 pulsotypes (5 isolates) and on IncFII plasmids in 1 pulsotype (2 isolates). As was the case with blaOXA-48 acquisition, the blaCTX-M-15 gene was acquired by different lineages of each clone on separate occasions.

IncR plasmids carrying the blaCTX-M-15 gene coharbored very diverse resistance genes (e.g., TEM-1 and OXA-1 β-lactamases, Qnr proteins B1 and B66, type Ib 3″-O-phosphotransferases, type Id 6ʹ-O-phosphotransferases, type Ib-cr 6ʹ-N-acetyltransferases, and type IIa 3′-N-acetyltransferases). IncR plasmids from pulsotypes P02 and P04 (both belonging to ST15) harbored the same resistance genes, and IncR plasmids from P10 and P13 similarly shared the same resistance determinants. The other 8 IncR plasmids analyzed carried different resistance genes (Table 2). These results support the idea that different resistance determinants were captured separately over time.

TABLE 2.

Antibiotic resistance genes located on sequenced IncR plasmids

ST Pulsotype Isolate Genea
blaTEM-1B blaOXA-1 blaSHV-28 strA-strB aac(6')Ib-cr aac(3)-IIa sul2 catA2 catB4 dfrA14 qnrB1 qnrB66 tetA
ST15 P01 2014081 + + +
ST15 P02 2014127 + + + + + + +
ST15 P03 2014028b + + +
ST15 P04 2015254 + + + + + + +
ST15 P05 2014142 + + + + + + + +
ST15 P07 2014090b
ST11 P08 2014126 + + + + +
ST11 P09 2015083 + + + + + + + +
ST11 P10 2015013 + + + + + + + +
ST1 P13 2015017 + + + + + + + +
ST391 P23 2015141 + + + + +
ST836 P26 2014139 + + + + + + +
a

All plasmids carried the blaCTX-M-15 gene. +, presence; −, absence; blaTEM-1B, gene encoding the β-lactamase TEM-1B; blaOXA-1, gene encoding the β-lactamase OXA-1; blaSHV-28, gene encoding the β-lactamase SHV-28; strA-strB, pair of genes encoding 3ʺ-O-phosphotransferase type Ib and 6ʹ-O-phosphotransferase type Id, respectively; aac(6ʹ)Ib-cr, gene encoding 6ʹ-N-aminoglycoside acetyltransferase type Ib-cr; aac(3)-IIa, gene encoding 3ʹ-N-acetyltransferase type IIa; sul2, gene encoding dihydropteroate synthetase; catA2, gene encoding chloramphenicol acetyltransferase type A2; catB4, gene encoding chloramphenicol acetyltransferase type B4; dfrA14, gene encoding dihydrofolate reductase type II14; qnrB1, gene encoding the Qnr B1 protein; qnrB66, gene encoding the Qnr B66 protein; tetA, gene encoding the efflux protein type A.

b

A transformant could not be obtained from these 2 pulsotypes, and both IncR and resistance determinants were obtained from WGS of clinical isolates bearing only 1 plasmid.

A major limitation of our study is that the collection studied was based on the estimated OXA-48-producing K. pneumoniae population in our region in 2014 and 2015. It was not obligatory to send isolates to the PIRASOA program laboratory (although in fact most isolates obtained from nosocomial outbreaks or clusters were sent). However, centralized analysis of isolates was able to demonstrate the spread of the same lineage of OXA-48 producers between hospitals in the same province and between different provinces in our region, which was not previously suspected even for sporadic cases. It should be borne in mind, however, that detection of the same lineage in different centers could also be due to recent transmission between institutions or to unknown long-term transmission in the community. Another limitation of our study is that all isolates belonging to the same pulsotype were considered to share the same OXA-48 plasmid and genetic platform. The individual location of the gene was not studied for every isolate, but the genes were very close genetically (only 1 band of difference) and were found in the same area.

Conclusions.

In summary, the spread of OXA-48-producing K. pneumoniae in the south of Spain is mainly due to interhospital dissemination of ST15 and ST11 clones. Our results suggest that lineages of the same clone captured blaOXA-48, blaCTX-M-15, and resistance genes on separate occasions. The greater diversity of the genetic platform of blaOXA-48, compared with the CTX-M-15 plasmids, could indicate that successful clones acquired CTX-M-15 first and then OXA-48. Transmission of OXA-48 producers should lead to a review of the considerations for regional patient transfer, as well as local hospital measures, including both patient tracking and rapid detection of successful clones.

MATERIALS AND METHODS

Bacterial isolates.

Between March 2014 and December 2015, 56 OXA-48-like-producing isolates were analyzed. The OXA-48-producing isolates came from 16 hospitals located in 7 of the 8 provinces of Andalusia (1 to 17 isolates/hospital); the hospitals were arbitrarily assigned numbered names of H1 to H16.

Bacterial identification and drug susceptibility testing.

The isolates were identified using matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) mass spectrometry (MALDI-TOF Biotyper 3.1; Microflex Bruker, Madrid, Spain). Susceptibility testing was performed with commercial microdilution panels (MicroScan; Beckman Coulter, Madrid, Spain), using EUCAST breakpoints (35). Screening for ESBL and plasmid-encoded AmpC (pAmpC) production was performed with the double-disc synergy test on Mueller-Hinton (MH) agar and MH agar supplemented with 200 mg/liter cloxacillin. The β-Carba test (Bio-Rad, Madrid, Spain) was used to check for imipenem hydrolysis (36). Initial carbapenemase characterization was performed with combined-disk tests employing meropenem plus inhibitors and temocillin susceptibility disks, according to EUCAST guidelines (10).

Characterization of ESBL and carbapenemase genes and genetic platforms of OXA-48-like-encoding genes.

The presence of genes encoding ESBLs (blaTEM, blaSHV, blaCTX-M-1 group, and blaCTX-M-9 group), pAmpC (blaMOX, blaCIT, blaCMY, blaDHA, blaFOX, blaACC, and blaEBC), and carbapenemases (blaOXA-48, blaKPC, blaIMP, blaVIM, and blaNDM) was determined using group-specific PCR primers and further sequencing (37, 38). The Tn1999 structure of blaOXA-48 and blaOXA-245 genes from selected isolates was determined by PCR using specific primers (see Table S1 in the supplemental material) and further sequencing. The sequences obtained were compared with those in the GenBank database. The primers used did not differentiate between Tn1999.2, Tn1999.4, and Tn1999.5 variants.

Molecular epidemiology.

PFGE analysis of XbaI-digested DNA (http://www.cdc.gov/pulsenet) was used to determine the degree of genetic relatedness between isolates. Isolates differing by 2 or more bands in XbaI PFGE assays were assigned to different pulsotypes. A dendrogram was created with Fingerprinting 3.0 software (Bio-Rad), using the Dice coefficient with position tolerance settings of 1% optimization and 1.2% band position tolerance. The Institut Pasteur MLST scheme was used to characterize a subset of isolates representing different PFGE clusters (http://bigsdb.pasteur.fr/klebsiella/klebsiella.html). All pulsotypes assigned to the same MLST were considered to belong to the same clone.

Transformation assays and characterization of OXA-48 and CTX-M-15 plasmids.

A representative isolate of each pulsotype was selected for transformation assays. Plasmid DNA was extracted using the method described by Kieser (39) and was transformed by electroporation into E. coli DH10B (streptomycin-resistant). Transformants were selected on MacConkey agar (Becton, Dickinson France SA, Le Pont de Claix, France) supplemented with 0.125 mg/liter ertapenem or 2 mg/liter cefotaxime, to select transformants with blaOXA-48-like or blaCTX-M-15 genes, respectively. The presence of blaOXA-48-like in ertapenem-resistant transformants and, similarly, blaCTX-M-15 in cefotaxime-resistant transformants was confirmed by phenotypic and genotypic methods, as described above, and the presence of only 1 plasmid was confirmed after an extraction using the Kieser method (39).

Plasmids from transformants were classified into incompatibility groups using a PBRT scheme (30). For IncF subtyping, replicon sequence typing was performed, following the nomenclature of the Plasmid MLST databases web site (http://www.pubmlst.org/plasmid). The new PBRT scheme was used for differentiation of IncL and IncM plasmids (26).

Whole-genome sequencing.

WGS was used for analysis of genomes of transformants with plasmids that were not classified with the PBRT scheme and when only 1 plasmid was electroporated into E. coli DH10B, according to Kieser extraction. Genomic DNA was extracted from transformants and sequenced on the MiSeq platform (Illumina, San Diego, CA, USA), generating 300-bp paired-end reads. The library was prepared using the Nextera XT DNA library preparation kit (Illumina), involving DNA fragmentation, adaptor ligation, and amplification. Raw reads were quality filtered and assembled into contigs on CLC Genomics Workbench 10.0 (Qiagen, Madrid, Spain), using default software settings. An average coverage of 50× was observed. Plasmid replicons were then analyzed with the PlasmidFinder tool (https://cge.cbs.dtu.dk/services/PlasmidFinder), using a 95% identity threshold (40). Acquired resistance genes were analyzed using the ResFinder tool (https://cge.cbs.dtu.dk/services/ResFinder), using a 90% identity threshold (41).

Accession number(s).

The Fastq files corresponding to transformants or clinical isolates with CTX-M-15-bearing IncR plasmids and OXA-48-bearing IncM plasmids have been deposited in the GenBank database under accession no. PRJNA493254.

Supplementary Material

Supplemental file 1

ACKNOWLEDGMENTS

We thank the Reference Laboratory, Program for the Prevention and Control of Healthcare-Associated Infections and Antimicrobial Stewardship in Andalucía (PIRASOA, Servicio Andaluz de Salud), for their collaboration.

This work was supported by Plan Nacional de I+D+i 2013-2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0001), cofinanced by European Development Regional Fund “A way to achieve Europe,” operative program Intelligent Growth 2014-2020.

We have no conflicts of interest to declare.

Footnotes

Supplemental material for this article may be found at https://doi.org/10.1128/AAC.01396-18.

REFERENCES

  • 1.Lee C-R, Lee JH, Park KS, Kim YB, Jeong BC, Lee SH. 2016. Global dissemination of carbapenemase-producing Klebsiella pneumoniae: epidemiology, genetic context, treatment options, and detection methods. Front Microbiol 7:895. doi: 10.3389/fmicb.2016.00895. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Albiger B, Glasner C, Struelens MJ, Grundmann H, Monnet DL. 2015. Carbapenemase-producing Enterobacteriaceae in Europe: assessment by national experts from 38 countries, May 2015. Euro Surveill 20:30062. doi: 10.2807/1560-7917.ES.2015.20.45.30062. [DOI] [PubMed] [Google Scholar]
  • 3.Poirel L, Héritier C, Tolün V, Nordmann P. 2004. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother 48:15–22. doi: 10.1128/AAC.48.1.15-22.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Dimou V, Dhanji H, Pike R, Livermore DM, Woodford N. 2012. Characterization of Enterobacteriaceae producing OXA-48-like carbapenemases in the UK. J Antimicrob Chemother 67:1660–1665. doi: 10.1093/jac/dks124. [DOI] [PubMed] [Google Scholar]
  • 5.Oteo J, Saez D, Bautista V, Fernández-Romero S, Hernández-Molina JM, Pérez-Vázquez M, Aracil B, Campos J. 2013. Carbapenemase-producing Enterobacteriaceae in Spain in 2012. Antimicrob Agents Chemother 57:6344–6347. doi: 10.1128/AAC.01513-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Poirel L, Bonnin RA, Nordmann P. 2012. Genetic features of the widespread plasmid coding for the carbapenemase OXA-48. Antimicrob Agents Chemother 56:559–562. doi: 10.1128/AAC.05289-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Giani T, Conte V, Di Pilato V, Aschbacher R, Weber C, Larcher C, Rossolini GM. 2012. Escherichia coli from Italy producing OXA-48 carbapenemase encoded by a novel Tn1999 transposon derivative. Antimicrob Agents Chemother 56:2211–2213. doi: 10.1128/AAC.00035-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Potron A, Nordmann P, Rondinaud E, Jaureguy F, Poirel L. 2013. A mosaic transposon encoding OXA-48 and CTX-M-15: towards pan-resistance. J Antimicrob Chemother 68:476–477. doi: 10.1093/jac/dks397. [DOI] [PubMed] [Google Scholar]
  • 9.Skalova A, Chudejova K, Rotova V, Medvecky M, Studentova V, Chudackova E, Lavicka P, Bergerova T, Jakubu V, Zemlickova H, Papagiannitsis CC, Hrabak J. 2017. Molecular characterization of OXA-48-like-producing Enterobacteriaceae in the Czech Republic and evidence for horizontal transfer of pOXA-48-like plasmids. Antimicrob Agents Chemother 61:e01889-16. doi: 10.1128/AAC.01889-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.EUCAST. 2017. EUCAST guideline for the detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance. http://www.eucast.org/resistance_mechanisms.
  • 11.Findlay J, Hopkins KL, Loy R, Doumith M, Meunier D, Hill R, Pike R, Mustafa N, Livermore DM, Woodford N. 2017. OXA-48-like carbapenemases in the UK: an analysis of isolates and cases from 2007 to 2014. J Antimicrob Chemother 72:1340–1349. doi: 10.1093/jac/dkx012. [DOI] [PubMed] [Google Scholar]
  • 12.Jeon JH, Lee JH, Lee JJ, Park KS, Karim AM, Lee C-R, Jeong BC, Lee SH. 2015. Structural basis for carbapenem-hydrolyzing mechanisms of carbapenemases conferring antibiotic resistance. Int J Mol Sci 16:9654–9692. doi: 10.3390/ijms16059654. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Oteo J, Hernandez JM, Espasa M, Fleites A, Saez D, Bautista V, Perez-Vazquez M, Fernandez-Garcia MD, Delgado-Iribarren A, Sanchez-Romero I, Garcia-Picazo L, Miguel MD, Solis S, Aznar E, Trujillo G, Mediavilla C, Fontanals D, Rojo S, Vindel A, Campos J. 2013. Emergence of OXA-48-producing Klebsiella pneumoniae and the novel carbapenemases OXA-244 and OXA-245 in Spain. J Antimicrob Chemother 68:317–321. doi: 10.1093/jac/dks383. [DOI] [PubMed] [Google Scholar]
  • 14.Mairi A, Pantel A, Sotto A, Lavigne J-P, Touati A. 2018. OXA-48-like carbapenemases producing Enterobacteriaceae in different niches. Eur J Clin Microbiol Infect Dis 37:587–604. doi: 10.1007/s10096-017-3112-7. [DOI] [PubMed] [Google Scholar]
  • 15.Markovska R, Stoeva T, Schneider I, Boyanova L, Popova V, Dacheva D, Kaneva R, Bauernfeind A, Mitev V, Mitov I. 2015. Clonal dissemination of multilocus sequence type ST15 KPC-2-producing Klebsiella pneumoniae in Bulgaria. APMIS 123:887–894. doi: 10.1111/apm.12433. [DOI] [PubMed] [Google Scholar]
  • 16.Oteo J, Ortega A, Bartolomé R, Bou G, Conejo C, Fernández-Martínez M, González-López JJ, Martínez-García L, Martínez-Martínez L, Merino M, Miró E, Mora M, Navarro F, Oliver A, Pascual Á, Rodríguez-Baño J, Ruiz-Carrascoso G, Ruiz-Garbajosa P, Zamorano L, Bautista V, Pérez-Vázquez M, Campos J. 2015. Prospective multicenter study of carbapenemase-producing Enterobacteriaceae from 83 hospitals in Spain reveals high in vitro susceptibility to colistin and meropenem. Antimicrob Agents Chemother 59:3406–3412. doi: 10.1128/AAC.00086-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Pantel A, Marchandin H, Prère M-F, Boutet-Dubois A, Brieu-Roche N, Gaschet A, Davin-Regli A, Sotto A, Lavigne J-P. 2015. Faecal carriage of carbapenemase-producing Gram-negative bacilli in hospital settings in southern France. Eur J Clin Microbiol Infect Dis 34:899–904. doi: 10.1007/s10096-014-2298-1. [DOI] [PubMed] [Google Scholar]
  • 18.Ben Tanfous F, Alonso CA, Achour W, Ruiz-Ripa L, Torres C, Ben Hassen A. 2017. First description of KPC-2-producing Escherichia coli and ST15 OXA-48-positive Klebsiella pneumoniae in Tunisia. Microb Drug Resist 23:365–375. doi: 10.1089/mdr.2016.0090. [DOI] [PubMed] [Google Scholar]
  • 19.Ouertani R, Limelette A, Guillard T, Brasme L, Jridi Y, Barguellil F, El Salabi A, de Champs C, Chouchani C. 2016. First report of nosocomial infection caused by Klebsiella pneumoniae ST147 producing OXA-48 and VEB-8 β-lactamases in Tunisia. J Glob Antimicrob Resist 4:53–56. doi: 10.1016/j.jgar.2015.10.002. [DOI] [PubMed] [Google Scholar]
  • 20.Girlich D, Bouihat N, Poirel L, Benouda A, Nordmann P. 2014. High rate of faecal carriage of extended-spectrum β-lactamase and OXA-48 carbapenemase-producing Enterobacteriaceae at a university hospital in Morocco. Clin Microbiol Infect 20:350–354. doi: 10.1111/1469-0691.12325. [DOI] [PubMed] [Google Scholar]
  • 21.Kovács K, Nyul A, Mestyán G, Melegh S, Fenyvesi H, Jakab G, Szabó H, Jánvári L, Damjanova I, Tóth Á. 2017. Emergence and interhospital spread of OXA-48-producing Klebsiella pneumoniae ST395 clone in western Hungary. Infect Dis (Lond) 49:231–233. doi: 10.1080/23744235.2016.1207252. [DOI] [PubMed] [Google Scholar]
  • 22.Czobor I, Novais Â, Rodrigues C, Chifiriuc MC, Mihăescu G, Lazăr V, Peixe L. 2016. Efficient transmission of IncFII Y and IncL plasmids and Klebsiella pneumoniae ST101 clone producing OXA-48, NDM-1 or OXA-181 in Bucharest hospitals. Int J Antimicrob Agents 48:223–224. doi: 10.1016/j.ijantimicag.2016.05.004. [DOI] [PubMed] [Google Scholar]
  • 23.Pano-Pardo JR, Ruiz-Carrascoso G, Navarro-San Francisco C, Gomez-Gil R, Mora-Rillo M, Romero-Gomez MP, Fernandez-Romero N, Garcia-Rodriguez J, Perez-Blanco V, Moreno-Ramos F, Mingorance J. 2013. Infections caused by OXA-48-producing Klebsiella pneumoniae in a tertiary hospital in Spain in the setting of a prolonged, hospital-wide outbreak. J Antimicrob Chemother 68:89–96. doi: 10.1093/jac/dks364. [DOI] [PubMed] [Google Scholar]
  • 24.Machuca J, López-Cerero L, Fernández-Cuenca F, Gracia-Ahufinger I, Ruiz-Carrascoso G, Rodríguez-López F, Pascual A. 2016. Characterization of an outbreak due to CTX-M-15-producing Klebsiella pneumoniae lacking the blaOXA-48 gene belonging to clone ST405 in a neonatal unit in southern Spain. J Antimicrob Chemother 71:2353–2355. doi: 10.1093/jac/dkw137. [DOI] [PubMed] [Google Scholar]
  • 25.Izdebski R, Baraniak A, Żabicka D, Machulska M, Urbanowicz P, Fiett J, Literacka E, Bojarska K, Kozińska A, Zieniuk B, Hryniewicz W, Gniadkowski M, Chrystyniuk P, Durnaś B, Kędzierska J, Mól A, Swoboda-Kopeć E, Wróblewska M, Tomanek E, Wcisło-Wach B. 2018. Enterobacteriaceae producing OXA-48-like carbapenemases in Poland, 2013–January 2017. J Antimicrob Chemother 73:620–625. doi: 10.1093/jac/dkx457. [DOI] [PubMed] [Google Scholar]
  • 26.Carattoli A, Seiffert SN, Schwendener S, Perreten V, Endimiani A. 2015. Differentiation of IncL and IncM plasmids associated with the spread of clinically relevant antimicrobial resistance. PLoS One 10:e0123063. doi: 10.1371/journal.pone.0123063. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Villa L, Carattoli A, Nordmann P, Carta C, Poirel L. 2013. Complete sequence of the IncT-type plasmid pT-OXA-181 carrying the blaOXA-181 carbapenemase gene from Citrobacter freundii. Antimicrob Agents Chemother 57:1965–1967. doi: 10.1128/AAC.01297-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Carrër A, Poirel L, Eraksoy H, Cagatay AA, Badur S, Nordmann P. 2008. Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. Antimicrob Agents Chemother 52:2950–2954. doi: 10.1128/AAC.01672-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Aubert D, Naas T, Héritier C, Poirel L, Nordmann P. 2006. Functional characterization of IS1999, an IS4 family element involved in mobilization and expression of β-lactam resistance genes. J Bacteriol 188:6506–6514. doi: 10.1128/JB.00375-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Carattoli A, Bertini A, Villa L, Falbo V, Hopkins KL, Threlfall EJ. 2005. Identification of plasmids by PCR-based replicon typing. J Microbiol Methods 63:219–228. doi: 10.1016/j.mimet.2005.03.018. [DOI] [PubMed] [Google Scholar]
  • 31.Villa L, García-Fernández A, Fortini D, Carattoli A. 2010. Replicon sequence typing of IncF plasmids carrying virulence and resistance determinants. J Antimicrob Chemother 65:2518–2529. doi: 10.1093/jac/dkq347. [DOI] [PubMed] [Google Scholar]
  • 32.Carattoli A. 2013. Plasmids and the spread of resistance. Int J Med Microbiol 303:298–304. doi: 10.1016/j.ijmm.2013.02.001. [DOI] [PubMed] [Google Scholar]
  • 33.Rodrigues C, Machado E, Ramos H, Peixe L, Novais Â. 2014. Expansion of ESBL-producing Klebsiella pneumoniae in hospitalized patients: a successful story of international clones (ST15, ST147, ST336) and epidemic plasmids (IncR, IncFIIK). Int J Med Microbiol 304:1100–1108. doi: 10.1016/j.ijmm.2014.08.003. [DOI] [PubMed] [Google Scholar]
  • 34.Baraniak A, Izdebski R, Fiett J, Gawryszewska I, Bojarska K, Herda M, Literacka E, Żabicka D, Tomczak H, Pewińska N, Szarata M, Ozorowski T, Milner A, Hryniewicz W, Gniadkowski M. 2016. NDM-producing Enterobacteriaceae in Poland, 2012–14: inter-regional outbreak of Klebsiella pneumoniae ST11 and sporadic cases. J Antimicrob Chemother 71:85–91. doi: 10.1093/jac/dkv282. [DOI] [PubMed] [Google Scholar]
  • 35.EUCAST. 2018. Clinical breakpoints and epidemiological cut-off values. http://www.eucast.org/clinical_breakpoints.
  • 36.Bernabeu S, Dortet L, Naas T. 2017. Evaluation of the β-CARBA test, a colorimetric test for the rapid detection of carbapenemase activity in Gram-negative bacilli. J Antimicrob Chemother 72:1646–1658. doi: 10.1093/jac/dkx061. [DOI] [PubMed] [Google Scholar]
  • 37.Rodríguez-Baño J, López-Cerero L, Navarro MD, Díaz de Alba P, Pascual A. 2008. Faecal carriage of extended-spectrum β-lactamase-producing Escherichia coli: prevalence, risk factors and molecular epidemiology. J Antimicrob Chemother 62:1142–1149. doi: 10.1093/jac/dkn293. [DOI] [PubMed] [Google Scholar]
  • 38.Miró E, Agüero J, Larrosa MN, Fernández A, Conejo MC, Bou G, González-López JJ, Lara N, Martínez-Martínez L, Oliver A, Aracil B, Oteo J, Pascual A, Rodríguez-Baño J, Zamorano L, Navarro F. 2013. Prevalence and molecular epidemiology of acquired AmpC β-lactamases and carbapenemases in Enterobacteriaceae isolates from 35 hospitals in Spain. Eur J Clin Microbiol Infect Dis 32:253–259. doi: 10.1007/s10096-012-1737-0. [DOI] [PubMed] [Google Scholar]
  • 39.Kieser T. 1984. Factors affecting the isolation of CCC DNA from Streptomyces lividans and Escherichia coli. Plasmid 12:19–36. doi: 10.1016/0147-619X(84)90063-5. [DOI] [PubMed] [Google Scholar]
  • 40.Carattoli A, Zankari E, García-Fernández A, Voldby Larsen M, Lund O, Villa L, Møller Aarestrup F, Hasman H. 2014. In silico detection and typing of plasmids using PlasmidFinder and plasmid multilocus sequence typing. Antimicrob Agents Chemother 58:3895–3903. doi: 10.1128/AAC.02412-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, Lund O, Aarestrup FM, Larsen MV. 2012. Identification of acquired antimicrobial resistance genes. J Antimicrob Chemother 67:2640–2644. doi: 10.1093/jac/dks261. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplemental file 1

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES